Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy. (19th May 2017)

• Record Type: Journal Article
• Authors: Broch, Kaspar; Leren, Ida S.; Saberniak, Jørg; Ueland, Thor; Edvardsen, Thor; Gullestad, Lars; Haugaa, Kristina H.
• Is Part Of: Biomarkers. Volume 22:Number 3/4(2017)
• Page Start: 367
• Page End: 371
• Publication Date: 2017-05-19
• Subjects: Arrhythmogenic right ventricular cardiomyopathy -- ST2 -- biomarker -- right ventricular function -- ventricular arrhythmia; Biochemical markers -- Periodicals; 610.28
• DOI: 10.1080/1354750X.2016.1278266
• Languages: English
• ISSNs: 1354-750X

Abstract

Abstract: Purpose: Diagnostic and prognostic evaluation remains challenging in arrhythmogenic right ventricular cardiomyopathy (ARVC). We measured plasma concentration of soluble ST2 (sST2) and assessed its association with right ventricular (RV) function and ventricular arrhythmias in patients with ARVC. Methods: We included patients with ARVC and genotype positive relatives. Soluble ST2 was determined by ELISA. We assessed myocardial function by echocardiography including strain by speckle tracking technique. Results: We included 44 subjects (age 41 ± 15 years, 21 (48%) female). Soluble ST2 was associated with RV global strain ( r = 0.44; p = 0.008), as well as with left ventricular (LV) function. Plasma levels of sST2 were higher in patients with ventricular arrhythmias than in patients without ventricular arrhythmias (35 ± 13 ng/mL vs. 26 ± 7 ng/mL, p = 0.009). The association between sST2 and ventricular arrhythmias remained significant even after adjusting for RV function (Wald = 5.2; p = 0.02). Conclusions: Soluble ST2 is associated with RV and LV function in patients with ARVC. Soluble ST2 may aid in the determination of disease severity in ARVC.